By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


FibroGen, Inc. 

225 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-866-7200 Fax: 650-866-7202



Company News
FibroGen (FGEN) Announces Pricing Of Follow-On Offering Of Common Stock 8/16/2017 8:35:01 AM
FibroGen (FGEN) Announces Proposed Follow-On Offering Of Common Stock 8/15/2017 7:47:21 AM
FibroGen (FGEN) Reports Second Quarter 2017 Financial Results 8/8/2017 1:20:49 PM
FibroGen (FGEN) Announces Positive Topline Results From Phase II Study Of Pamrevlumab In Idiopathic Pulmonary Fibrosis 8/8/2017 8:13:02 AM
FibroGen (FGEN) To Report Second Quarter Financial Results On Monday, August 7, 2017 8/1/2017 1:12:19 PM
FibroGen (FGEN) Granted Orphan Drug Designation For Pamrevlumab In The Treatment Of Pancreatic Cancer 6/22/2017 11:13:06 AM
European Patent Office Maintains FibroGen (FGEN) Patent Relating To Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology 6/5/2017 12:54:44 PM
FibroGen (FGEN) Reports First Quarter 2017 Financial Results 5/10/2017 11:09:09 AM
FibroGen (FGEN)'s Novel Anemia Treatment Meets Phase III Endpoints In China 1/31/2017 3:30:01 PM
Astellas (ALPMY) And FibroGen (FGEN) Announce First Patient Treated In Phase III Studies And Positive Phase II Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 7/26/2016 8:17:58 AM